CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOACaptura de pantalla 2022 09 14 a las 10.27.10    

Intracellular Signalling in Inflammatory Processes

Research summary:

The incidence of inflammatory and autoimmune diseases has increased in the last 30 years, particularly among developed countries. Thus, there is a need for the development of novel therapies to treat these pathologies. Interleukin 23 (IL-23) is a pro-inflammatory cytokine whose excessive production plays a fundamental role in the development of several inflammatory diseases such as Crohn's disease, ulcerative colitis, multiple sclerosis and psoriasis. The pathological consequences of excessive IL-23 signalling have been linked to its ability to promote effector functions of distinct populations of T lymphocytes: CD4 helper subset Th17 and the TCRγδ T17γδ. Despite the prominent role described for IL-23 in inflammatory diseases, the precise molecular mechanisms by which IL-23 induces pathogenic functions on T lymphocytes remain largely unknown. Our lab is interested in the characterisation of the signalling network triggered by IL-23 using novel techniques such as large-scale quantitative proteomics and phosphoproteomic approaches to uncover novel mediators of IL-23 actions. The underlying aim of this strategy is the development of novel therapeutic tools based on the interference with intracellular signalling pathways. Currently, we are characterising novel signalling mediators that link IL-23 with processes such as cell migration and metabolism. Our work extends beyond the identification of potential targets, and combines pharmacological and genetic approaches to determine the contribution of specific signalling mediators in murine models of IL-23-mediated inflammatory pathologies.

Maria Navarro figure1000px

3D animated video: How does IL-23 signaling cascade promote the development of inflammatory diseases? Psoriasis, multiple sclerosis and inflammatory bowl diseases. Cells 2020 Sep 7;9(9):E2044, PMID: 32906785. PLoS Biol. 2020 Mar 23;18(3):e3000646, PMID: 32203518.


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Cayuela GraciaIgnacio2274546Estudiante TFM
Fraile RodríguezRebeca2274546Estudiante TFG
Navarro LobatoMaría de las Nieves114.34453marian.navarro(at)cbm.csic.esE.Científicos Titulares de Organismos Públicos de Investigación
Santiago YebraJorge2274546jsantiago(at)cbm.csic.esM3 Predoc.formación

Relevant publications:

  • Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing.
    Navarro MN*, Gómez de Las Heras MM, Mittelbrunn M*. (*co-corresponding authors)Br J Pharmacol. 2022 May;179(9):1839-1856. doi: 10.1111/bph.15477. Epub 2021 May 12. PMID: 33817782 Free PMC article. Review.
  • Mutation of the Polyproline Sequence in CD3ε Evidences TCR Signaling Requirements for Differentiation and Function of Pro-Inflammatory Tγδ17 Cells. Borroto A, Alarcón B, Navarro MN. Front Immunol. 2022 Mar 31;13:799919. doi: 10.3389/fimmu.2022.799919. eCollection 2022. PMID: 35432331
  • Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities. Pastor-Fernández G, Mariblanca IR, Navarro MN. Cells. 2020 Sep 7;9(9):E2044. doi: 10.3390/cells9092044. PMID: 32906785 Review.
  • Álvarez-Salamero C, Castillo-González R, Pastor-Fernández G, Mariblanca IR, Pino J, Cibrian D, Navarro MN. IL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics. PLoS Biol. 2020 Mar 23;18(3):e3000646. doi: 10.1371/journal.pbio.3000646. eCollection 2020 Mar. PMID:32203518.
  • Álvarez-Salamero C, Castillo-González R, Navarro MN. Lighting Up T Lymphocyte Signaling with Quantitative Phosphoproteomics. Front Immunol. 2017 Aug 9;8:938. doi: 10.3389/fimmu.2017.00938. eCollection 2017. Review. PubMed PMID: 28848546; PubMed Central PMCID: PMC5552657.
  • Navarro MN, Feijoo-Carnero C, Arandilla AG, Trost M, Cantrell DA. Protein kinase D2 is a digital amplifier of T cell receptor-stimulated diacylglycerol signaling in naïve CD8⁺ T cells. Sci Signal. 2014 Oct 21;7(348):ra99. doi: 10.1126/scisignal.2005477. PubMed PMID: 25336615; PubMed Central PMCID: PMC4768351.
  • Navarro MN, Goebel J, Hukelmann JL, Cantrell DA. Quantitative phosphoproteomics of cytotoxic T cells to reveal protein kinase d 2 regulated networks. Mol Cell Proteomics. 2014 Dec;13(12):3544-57. doi: 10.1074/mcp.M113.037242. Epub 2014 Sep 29. PubMed PMID: 25266776; PubMed Central PMCID: PMC4256504.
  • Navarro MN, Cantrell DA. Serine-threonine kinases in TCR signaling. Nat Immunol. 2014 Sep;15(9):808-14. doi: 10.1038/ni.2941. Review. PubMed PMID: 25137455.
  • Navarro MN, Goebel J, Feijoo-Carnero C, Morrice N, Cantrell DA. Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol. 2011 Apr;12(4):352-61. doi: 10.1038/ni.2008. Epub 2011 Mar 13. PubMed PMID: 21399638; PubMed Central PMCID: PMC3110993.

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand


What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: